Theriva Biologics (TOVX) Other Working Capital Changes (2020 - 2026)
Theriva Biologics (TOVX) posted quarterly Other Working Capital Changes of -$156000.0 for Q1 2026, down 20.0% year-over-year from -$195000.0 in Q1 2025, and down 4.7% quarter-over-quarter from -$149000.0 in Q4 2025.
Theriva Biologics (TOVX) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Other Working Capital Changes for 7 consecutive years, with -$156000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 20.0% year-over-year to -$156000.0; the TTM figure through Mar 2026 stood at -$588000.0 (down 18.31% YoY), while the FY2025 annual figure was -$562000.0, down 16.6% from the prior year.
- Other Working Capital Changes retreated to -$156000.0 in Q1 2026 per TOVX's latest filing, from -$149000.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $1.1 million in Q4 2022 and bottomed at -$1.5 million in Q3 2023.
- Historically, Other Working Capital Changes has averaged -$164764.7 across 5 years, with a median of -$251000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes jumped 106.25% — and 2023, when it slumped 3766.67%.
- Theriva Biologics' Other Working Capital Changes stood at $3000.0 in 2022, then plunged by 3766.67% to -$110000.0 in 2023, then decreased by 13.64% to -$125000.0 in 2024, then retreated by 19.2% to -$149000.0 in 2025, then decreased by 4.7% to -$156000.0 in 2026.
- Business Quant data shows TOVX's Other Working Capital Changes at -$156000.0 in Q1 2026, -$149000.0 in Q4 2025, and -$145000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Theriva Biologics | 10.90 Mn | 10.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -122,000.00 |
| Jun 30, 2026 | -122,000.00 |
| Jun 30, 2026 | -122,000.00 |
| Mar 31, 2026 | -156,000.00 |
| Mar 31, 2026 | -156,000.00 |
| Mar 31, 2026 | -156,000.00 |
| Dec 31, 2025 | -149,000.00 |
| Dec 31, 2025 | -149,000.00 |
| Dec 31, 2025 | -149,000.00 |
| Sep 30, 2025 | -145,000.00 |
| Sep 30, 2025 | -145,000.00 |
| Sep 30, 2025 | -145,000.00 |
| Jun 30, 2025 | -138,000.00 |
| Jun 30, 2025 | -138,000.00 |
| Jun 30, 2025 | -138,000.00 |
| Mar 31, 2025 | -130,000.00 |
| Mar 31, 2025 | -130,000.00 |
| Mar 31, 2025 | -130,000.00 |
| Dec 31, 2024 | -125,000.00 |
| Dec 31, 2024 | -125,000.00 |